Danvatirsen (Synonyms: AZD9150) |
Catalog No.GC65020 |
Danvatirsen은 잠재적인 항종양 활성을 가진 STAT3를 표적으로 하는 안티센스 올리고뉴클레오티드입니다. Danvatirsen은 STAT3 mRNA에 결합하여 전사체의 번역을 억제합니다. STAT3 발현 억제는 종양 세포 사멸을 유도하고 종양 세포 성장을 감소시킵니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1402357-06-5
Sample solution is provided at 25 µL, 10mM.
Danvatirsen is an antisense oligonucleotide targeting STAT3 with potential antitumor activity. Danvatirsen binds to STAT3 mRNA, thereby inhibiting translation of the transcript. Suppression of STAT3 expression induces tumor cell apoptosis and decreases tumor cell growth.
[1]. Hong D, Kurzrock R, Kim Y, et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med. 2015;7(314):314ra185.
[2]. Reilley MJ, McCoon P, Cook C, et al. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. J Immunother Cancer. 2018;6(1):119.
[3]. Odate S, Veschi V, Yan S, Lam N, Woessner R, Thiele CJ. Inhibition of STAT3 with the Generation 2.5 Antisense Oligonucleotide, AZD9150, Decreases Neuroblastoma Tumorigenicity and Increases Chemosensitivity. Clin Cancer Res. 2017;23(7):1771-1784.
[4]. Shastri A, Choudhary G, Teixeira M, et al. Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells. J Clin Invest. 2018;128(12):5479-5488.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *